This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, A. W.M. Articles by Lau, J. T. Search for Related Content PubMed PubMed Citation Articles by Lee, A. W.M. Articles by Lau, J. T. Social Bookmarking                            What's this?

Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group

From the Departments of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, Tuen Mun Hospital, and Queen Mary Hospital, Hong Kong, China; Department of Biostatistics, University of Wisconsin Medical School, Madison, WI; Comprehensive Cancer Trials Unit, Chinese University of Hong Kong, China; and Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada

Address reprint requests to Anne W.M. Lee, Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Rd, Chai Wan, Hong Kong; e-mail: awmlee{at}ha.org.hk

PURPOSE: This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease.

PATIENTS AND METHODS: Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m² on days 1, 22, and 43, followed by cisplatin 80 mg/m² and fluorouracil 1,000 mg/m²/d for 96 hours starting on days 71, 99, and 127.

RESULTS: From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024).

CONCLUSION: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio.

Supported by grants from the Hong Kong Cancer Fund, Ho Hung Chiu Medical Foundation Limited, and the Hong Kong Anti-Cancer Society, Hong Kong.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004), and the 46th Annual Meeting of the American Society of Therapy Radiation Oncology, Atlanta, GA, October 3-7, 2004.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. B. Y. Ma, E. P. Hui, S. C. C. Wong, S. Y. Tung, K. K. Yuen, A. King, S. L. Chan, S. F. Leung, M. K. Kam, B. K. H. Yu, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms Ann. Onc., November 1, 2009; 20(11): 1854 - 1859. [Abstract] [Full Text] [PDF]

				N. Lee, J. Harris, A. S. Garden, W. Straube, B. Glisson, P. Xia, W. Bosch, W. H. Morrison, J. Quivey, W. Thorstad, et al. Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225 J. Clin. Oncol., August 1, 2009; 27(22): 3684 - 3690. [Abstract] [Full Text] [PDF]

				C Y CHEN, F HAN, C ZHAO, L X LU, Y SUN, X F LIU, and T X LU Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone Br. J. Radiol., June 1, 2009; 82(978): 452 - 458. [Abstract] [Full Text] [PDF]

				A. T. C. Chan, E. Felip, and On behalf of the ESMO Guidelines Working Group Nasopharyngeal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv123 - iv125. [Full Text] [PDF]

				N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]

				J. K. Salama, T. Y. Seiwert, and E. E. Vokes Chemoradiotherapy for Locally Advanced Head and Neck Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126. [Full Text] [PDF]

				J. Ma, L. Liu, L. Tang, J. Zong, A. Lin, T. Lu, N. Cui, C. Cui, and L. Li Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma: Prognostic Value and Staging Categories Clin. Cancer Res., March 1, 2007; 13(5): 1445 - 1452. [Abstract] [Full Text] [PDF]

				Y. Demizu, R. Sasaki, T. Soejima, T. Maruta, Y. Okamoto, K. Yamada, E. Yoden, Y. Ejima, Y. Ota, H. Ishida, et al. Efficacy and Feasibility of Cisplatin-Based Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 620 - 625. [Abstract] [Full Text] [PDF]